BRAF and central nervous system cancer: Nobre et al. [75] collected clinical, imaging, molecular and outcome information from pediatric patients with low- and high-grade BRAF p.V600E-mutated gliomas treated with a BRAF inhibitor (dabrafenib or vemurafenib).